Tade Brad L. 4
4 · ADMA BIOLOGICS, INC. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
ADMA BIOLOGICS (ADMA) CFO Brad L. Tade Sells 6,479 Shares to Cover Taxes
What Happened
- Brad L. Tade, Chief Financial Officer and Treasurer of ADMA BIOLOGICS, had 6,479 shares withheld by the company on February 19, 2026 to satisfy mandatory tax withholding upon the vesting of restricted stock units (RSUs). The withheld shares are reported at $16.32 per share, for a total value of $105,737. This was a withholding to cover taxes (transaction code F), not an open-market sale.
Key Details
- Transaction date: 2026-02-19; filing date (Form 4): 2026-02-23 (filed within the required reporting window).
- Shares withheld: 6,479 @ $16.32 = $105,737 (tax withholding; not an open-market sale).
- Shares/awards noted in filing: several unvested RSU pools listed — 46,671 of 62,227 RSUs (granted Feb 19, 2025), 54,300 RSUs (granted Jul 24, 2024), 37,500 RSUs (granted Feb 26, 2024), 50,000 RSUs (granted Jun 26, 2023) — each vesting quarterly over four years and settle into common stock upon vesting.
- Filing also notes 44,469 shares acquired via open-market purchases and RSU vesting (after withholding to cover taxes).
- Footnote: F = shares withheld by issuer to satisfy mandatory tax withholding on RSU vesting (not a sale).
Context
- This was a routine tax-withholding transaction tied to RSU vesting (cashless/withhold-to-cover), which reduces the number of shares issued to the insider but does not reflect an active decision to sell shares on the open market. For retail investors, purchases by insiders tend to draw more attention than routine withholdings; this filing simply documents tax-related share withholding following vesting.
Insider Transaction Report
Form 4
Tade Brad L.
CFO and Treasurer
Transactions
- Tax Payment
Common Stock
[F1][F2][F3][F4]2026-02-19$16.32/sh−6,479$105,737→ 232,940 total
Footnotes (4)
- [F1]Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.
- [F2]Includes, as of the transaction date, (i) 46,671 unvested RSUs out of 62,227 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
- [F3](continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
- [F4](continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 44,469 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes.
Signature
/s/ Brad L. Tade, by Michael A. Goldstein as Attorney-in-fact|2026-02-23